Silexion Therapeutics Ltd.
SLXNWNASDAQHealthcare● Active
$0.03
$-0.00(-7.82%)
Market Cap$18512
P/E Ratio—
52W High$0.0999
52W Low$0.0272
Silexion Therapeutics Ltd. (SLXNW) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SLXNW · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$8.50
Est. -$12.90 · +34.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
SLXNW reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$13.10 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 18, 2026 | -$12.90 | -$8.50 | +34.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 17, 2026 | -$11.20 | -$23.85 | -113.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$3.40 | -$2.88 | +15.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$3.15 | -$4.32 | -37.1% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$3.30 | -$0.26 | +92.2% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$13.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Beat
EPS Actual
-$8.50
EPS Est.
-$12.90
EPS Surpr.
+34.1%
Revenue
—
Q1 FY2026
Mar 17, 2026Miss
EPS Actual
-$23.85
EPS Est.
-$11.20
EPS Surpr.
-113.0%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$2.88
EPS Est.
-$3.40
EPS Surpr.
+15.3%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$4.32
EPS Est.
-$3.15
EPS Surpr.
-37.1%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$3.30
EPS Surpr.
+92.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-5.00 | $-5.00 | $-5.00 | 1 |
| Q3 FY2026 | $-13.30 | $-13.30 | $-13.30 | 1 |
| Q2 FY2026 | $-13.10 | $-13.10 | $-13.10 | 1 |
| Q1 FY2026 | $-12.90 | $-12.90 | $-12.90 | 1 |
| Q4 FY2025 | $-1.12 | $-1.12 | $-1.12 | 1 |
| Q3 FY2025 | $-3.40 | $-3.40 | $-3.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 18, 2026 | +34.1% | $0.01 | $0.01 | -10.00% |
| ▼ Q1 FY2026 | Mar 17, 2026 | -113.0% | $0.02 | $0.02 | +0.59% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +15.3% | $0.03 | $0.04 | +19.82% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -37.1% | $0.03 | $0.03 | +0.76% |
| ▲ Q2 FY2025 | May 13, 2025 | +92.2% | $0.05 | $0.04 | -2.17% |
Q2 FY2026-10.00%
Report Date
May 18, 2026
EPS Beat/Miss
+34.1%
Price Before
$0.01
Price After
$0.01
Q1 FY2026+0.59%
Report Date
Mar 17, 2026
EPS Beat/Miss
-113.0%
Price Before
$0.02
Price After
$0.02
Q4 FY2025+19.82%
Report Date
Nov 12, 2025
EPS Beat/Miss
+15.3%
Price Before
$0.03
Price After
$0.04
Q3 FY2025+0.76%
Report Date
Aug 12, 2025
EPS Beat/Miss
-37.1%
Price Before
$0.03
Price After
$0.03
Q2 FY2025-2.17%
Report Date
May 13, 2025
EPS Beat/Miss
+92.2%
Price Before
$0.05
Price After
$0.04
Avg Beat Reaction+2.55%
Avg Miss Reaction+0.68%
Beat Rate3 / 5 quarters
Largest Move+19.82% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SLXNW ends December
Silexion Therapeutics Ltd. (SLXNW) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-8.50 — beating the analyst consensus of $-12.90 by +34.1%. The next SLXNW earnings date is expected around September 1, 2026.
Each quarter, investors track SLXNW earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SLXNW revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SLXNW's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SLXNW earnings · 5 questionsSilexion Therapeutics Ltd.'s next earnings report is expected around September 1, 2026. SLXNW typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SLXNW historically reports after market close (AMC).
SLXNW earnings datewhen is SLXNW earningsSLXNW next earnings datewhen does SLXNW report earningsSLXNW earnings calendar
▸ Source: FMP · Silexion Therapeutics Ltd. SEC filings · US GAAP · Silexion Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026